Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 896

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 896
---
 ​ | ​ | ​                                   | ​ |          — | ​ | ​ | ​ | ​      | ​ |      — | ​ | ​ | ​ | ​ | ​           | ​ |          — | ​ | ​ | ​ | ​      | ​ |  — | ​ | ​ | ​ | ​                        | ​ |   — | ​ | ​ | ​ | ​                  | ​ | -17,347 | ​ | ​ | ​ | ​                                 | ​ |   — | ​ | ​ | ​ | ​                         | ​ | -17,347 | ​ | ​ |
| Balances as of December 31, 2023         | ​ | ​ | ​                                   | ​ | 29,555,538 | ​ | ​ | ​ | ​      | $ | 85,503 | ​ | ​ | ​ | ​ | ​           | ​ | 19,134,164 | ​ | ​ | ​ | ​      | $ | 19 | ​ | ​ | ​ | ​                        | $ | 762 | ​ | ​ | ​ | ​                  | $ | -62,839 | ​ | ​ | ​ | ​                                 | $ |   — | ​ | ​ | ​ | ​                         | $ | -62,058 | ​ | ​ |

The accompanying notes are an integral part of these financial statements. F-93

TABLE OF CONTENTS

Tvardi Therapeutics, Inc. Statements of Cash Flows
(Amounts in thousands)

| ​                                                                                            
 ​                                                                                            | ​ 
 ​ | ​ 
 ​ | For the Year Ended December 31, 
 2023                            |   |         |   | ​ | ​ | 2022 |   |         |   | ​ 
 ​ |
|:---------------------------------------------------------------------------------------------|:--|:--|:--------------------------------|:--|--------:|:--|:--|:--|:-----|:--|--------:|:--|:--|
| Cash flows from operating activities:                                                        | ​ | ​ | ​                               | ​ |       ​ | ​ | ​ | ​ | ​    | ​ |       ​ | ​ | ​ |
| Net loss                                                                                     | ​ | ​ | ​                               | $ | -17,347 | ​ | ​ | ​ | ​    | $ | -20,542 | ​ | ​ |
| Adjustments to reconcile net loss to net cash used in operating activities:                  | ​ | ​ | ​                               | ​ |       ​ | ​ |